peptidylprolyl isomerase A pseudogene 85Genealiases: []
Q-omics provides the consensus-scored PPIAP85 profile across patient tissues and cancer cell-line models. PPIAP85 expression is associated with patient survival in 11 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, PPIAP85 is differentially expressed in 4, with the highest sampling consensus in LUAD. Additionally, PPIAP85 RNA expression shows 6,321 significant pathway-activity associations, with the highest sampling consensus in STAD. Together, these results highlight KIRC, LUAD, and STAD as cancer lineages where PPIAP85 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for PPIAP85 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes PPIAP85 survival associations across molecular data types. PPIAP85 RNA expression shows survival associations in the most cancer types (11). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible PPIAP85 RNA expression–survival associations across cancer types. High PPIAP85 expression shows unfavorable associations in KIRC, ACC, KICH, LIHC and READ, but favorable associations in HNSC. The KIRC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .001). Together, the overview and detailed table identify KIRC as the clearest survival context for PPIAP85 RNA expression.
This table summarizes PPIAP85 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 4. The strongest signals are observed in LIHC for RNA.
This table ranks reproducible tumor–normal expression differences for PPIAP85. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. PPIAP85 shows lower tumor expression in THCA and higher tumor expression in LUAD, LIHC and LUSC. The LUAD box plot shows higher PPIAP85 RNA expression in tumor versus normal tissue (log2 FC = +0.058, t-test p = .017).
This table shows molecular features associated with PPIAP85 in patient tissues and cancer cell lines. In patient samples, PPIAP85 shows the broadest associations at the RNA and protein expression levels, with STAD recurring as the lineage with the largest associated feature set.
